Last 47 quarters of trend data · Healthcare · Specialty & Generic Drugs
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -93.55 | 41.54 | 61.59 | — | 20.61 | 5.80 | — | 9.82 | — | — | — | — | — | — | — | — | — | 0.20 | — | — | — |
| — | +616.2% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 6.16 | 7.40 | 8.12 | 5.28 | 3.99 | 3.53 | 6.80 | 3.72 | 8.75 | 19.84 | 21.09 | 12.92 | — | 24.09 | 21.98 | 11.36 | 0.73 | 0.79 | 2.12 | 2.06 | 3.07 |
| — | +109.9% | +19.4% | +42.0% | -54.4% | -82.2% | -67.8% | -71.2% | — | -17.6% | -4.0% | +13.7% | — | +2952.8% | +938.6% | +451.8% | -76.1% | -84.5% | -63.9% | -46.4% | -44.8% | |
| P/B Ratio | 0.75 | 0.95 | 0.87 | 0.70 | 0.46 | 0.49 | 0.40 | 0.36 | 0.71 | 0.67 | 0.92 | 0.89 | 1.15 | 1.35 | 1.14 | 1.49 | — | — | — | — | — |
| — | +92.7% | +118.1% | +93.6% | -35.5% | -26.7% | -56.6% | -59.1% | -38.7% | -50.3% | -19.3% | -40.5% | — | — | — | — | — | — | — | — | — | |
| P/FCF | 6.45 | 8.35 | 6.28 | 12.81 | 2.99 | 10.36 | 3.89 | 206.62 | — | 5.19 | 600.19 | — | — | — | — | 0.22 | 1.48 | 0.19 | — | — | — |
| — | -19.4% | +61.3% | -93.8% | — | +99.5% | -99.4% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.05 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | 55.98 | 6.38 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 62.1% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -26.9% | 100.0% | 100.0% | 100.0% | -198.1% | 81.9% | 83.4% | 74.9% | 74.6% | 79.2% |
| — | -37.9% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | +471.9% | 0.0% | 0.0% | 0.0% | +86.4% | +22.1% | +19.9% | +33.6% | -365.4% | +3.4% | +1.7% | -2.0% | -0.9% | -4.6% | |
| Operating Margin | -139.4% | -92.4% | -99.9% | -167.5% | -105.9% | -73.0% | -303.6% | -46.8% | -207.3% | -1191.9% | -364.9% | -320.9% | 3345.3% | -565.7% | -641.1% | 9685.6% | -99.2% | -66.0% | -135.7% | -189.5% | -157.1% |
| — | -26.6% | +67.1% | -258.1% | +48.9% | +93.9% | +16.8% | +85.4% | -106.2% | -110.7% | +43.1% | -103.3% | +3472.7% | -757.5% | -372.5% | +5211.5% | +36.9% | +56.9% | +7.9% | -23.6% | -21.7% | |
| Net Margin | -18.8% | 17.8% | 13.1% | -69.3% | 19.4% | 57.9% | -166.2% | 37.8% | -111.3% | -465.8% | -234.5% | -175.9% | 6373.6% | -552.4% | -866.1% | -2883.8% | -138.5% | 393.1% | -371.5% | -230.0% | -186.6% |
| — | -69.2% | +107.9% | -283.5% | +117.4% | +112.4% | +29.1% | +121.5% | -101.7% | +15.7% | +72.9% | +93.9% | +4702.7% | -240.5% | -133.2% | -1153.8% | +25.8% | +312.0% | -87.4% | -23.4% | -10.7% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -2.1% | 0.6% | 0.4% | -2.3% | 0.6% | 2.0% | -2.4% | 0.9% | -2.2% | -3.9% | -2.5% | -3.1% | -11.4% | -7.6% | -10.7% | -94.5% | — | — | — | — | — |
| — | -71.9% | +114.6% | -346.3% | +125.0% | +152.7% | +4.7% | +130.0% | +80.5% | +49.3% | +76.4% | +96.7% | — | — | — | — | — | — | — | — | — | |
| ROA | -1.5% | 0.4% | 0.3% | -1.6% | 0.4% | 1.4% | -1.7% | 0.6% | -1.5% | -2.7% | -1.7% | -1.9% | -6.5% | -4.3% | -4.8% | -29.6% | -20.7% | 80.3% | -47.4% | -22.7% | -22.6% |
| — | -71.3% | +114.9% | -352.2% | +125.8% | +154.2% | +1.4% | +134.2% | +76.4% | +37.8% | +64.2% | +93.6% | +68.6% | -105.3% | +89.9% | -30.7% | +8.4% | +523.6% | -153.4% | +3.4% | -32.5% | |
| ROIC | -11.5% | -2.5% | -2.2% | -4.3% | -2.3% | -1.9% | -3.1% | -0.8% | -2.9% | -6.7% | -2.6% | -4.1% | -5.1% | -7.5% | -13.7% | 506.8% | -41.7% | -31.9% | -49.0% | -73.8% | -90.9% |
| — | -34.6% | +30.2% | -440.3% | +20.3% | +72.2% | -18.4% | +80.6% | +44.1% | +10.7% | +80.8% | -100.8% | +87.7% | +76.4% | +72.0% | +786.7% | +54.1% | +52.6% | +0.1% | -37.7% | -142.5% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.23 | 0.20 | 0.22 | 0.23 | 0.24 | 0.24 | 0.26 | 0.26 | 0.27 | 0.27 | 0.27 | 0.27 | 0.29 | 0.27 | 0.27 | 0.25 | — | — | — | — | — |
| — | -15.3% | -17.1% | -13.5% | -13.5% | -11.8% | -4.2% | -4.1% | -6.6% | +2.1% | +1.6% | +9.7% | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.08 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 3.02 | 3.22 | 3.11 | 3.02 | 2.46 | 2.89 | 2.64 | 1.92 | 2.03 | 2.03 | 1.42 | 1.72 | 1.20 | 1.20 | 1.28 | 1.18 | 0.50 | 0.60 | 0.32 | 0.47 | 1.85 |
| — | +11.6% | +17.8% | +57.1% | +21.0% | +42.0% | +85.8% | +11.6% | +69.2% | +69.0% | +11.1% | +45.6% | +139.2% | +100.1% | +301.3% | +150.1% | -72.9% | -71.5% | -89.6% | -78.2% | -28.3% | |
| Quick Ratio | 3.02 | 3.22 | 3.11 | 3.02 | 2.46 | 2.89 | 2.64 | 1.92 | 2.03 | 2.06 | 1.42 | 1.72 | 1.20 | 1.20 | 1.28 | 1.18 | 0.46 | 0.56 | 0.28 | 0.44 | 1.77 |
| — | +11.6% | +17.8% | +57.1% | +21.0% | +40.0% | +85.8% | +11.6% | +69.2% | +71.4% | +11.1% | +45.6% | +159.0% | +113.4% | +349.0% | +167.2% | -73.8% | -71.9% | -90.3% | -78.2% | -25.6% | |
| Interest Coverage | -526.75 | — | — | -4148.00 | 17.67 | 273.50 | -596.50 | — | -188.00 | -209.00 | — | -17.64 | -70.70 | -52.64 | -45.20 | -1.02 | -9.30 | -3.94 | -3.33 | -5.49 | -5.50 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TXMD stock.
TherapeuticsMD, Inc.'s current P/E is -93.5x. The average P/E over the last 3 quarters is 41.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
TherapeuticsMD, Inc.'s current operating margin is -139.4%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking TherapeuticsMD, Inc.'s business trajectory between earnings reports.